- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03456063
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- St George Hospital; Cancer Care Centre
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital; Oncology
-
North Melbourne, Victoria, Australia, 3051
- Peter MacCallum Cancer Center
-
-
-
-
-
Linz, Austria, 4020
- Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Lungenkrankheiten
-
Linz, Austria, 4020
- Ordensklinikum Linz Elisabethinen
-
Wien, Austria, 1210
- Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie
-
Wien, Austria, 1140
- Klinik Penzing; Abteilung für Atemwegs- und Lungenkrankheiten
-
-
-
-
MG
-
Belo Horizonte, MG, Brazil, 30130-090
- Cenantron - Centro Avancado de Tratamento Oncologico
-
-
RS
-
Porto Alegre, RS, Brazil, 90040-373
- Hospital Nossa Senhora da Conceicao
-
-
SP
-
Sao Paulo, SP, Brazil, 01246-000
- Instituto do Cancer do Estado de Sao Paulo - ICESP
-
-
-
-
-
Shanghai, China, 200000
- Shanghai Chest Hospital
-
-
-
-
-
Angers, France, 49933
- CHU Angers
-
Lyon, France, 69008
- Centre Leon Berard
-
Saint Quentin, France, 02321
- Centre Hospitalier Saint Quentin
-
Saint-Mande, France, 94160
- Hopital d'Instruction des Armees de Begin
-
Strasbourg, France, 67091
- CHU Strasbourg - Nouvel Hopital Civil
-
Toulon, France, 83000
- Hôpital d'Instruction des Armées de Sainte Anne; Service de Pneumologie
-
-
-
-
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie
-
Gauting, Germany, 82131
- Asklepios-Fachkliniken Muenchen-Gauting; Onkologie
-
Gerlingen, Germany, 70839
- Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
-
Großhansdorf, Germany, 22927
- LungenClinic Großhansdorf GmbH; Klinische Forschung
-
Halle, Germany, 06120
- Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II
-
Oldenburg, Germany, 26121
- Pius-Hospital Oldenburg
-
Regensburg, Germany, 93053
- Klinikum der Univer Regenburg; Klinik und Poliklinik fuer Inn
-
Würzburg, Germany, 97074
- Missionsärztliche Klinik, Gemeinnützige Gesellschaft mbH
-
-
-
-
-
Budapest, Hungary, 1083
- Semmelweis Egyetem X; Pulmonologiai Klinika
-
-
-
-
-
Beer Sheva, Israel, 8410101
- Soroka Medical Center
-
Haifa, Israel, 3109601
- Rambam Health Care Campus; Oncology
-
Kfar-Saba, Israel, 4428164
- Meir Medical Center; Oncology
-
Tel Aviv, Israel, 6423906
- Sourasky / Ichilov Hospital; Dept. of Oncology
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00128
- Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica
-
-
Lombardia
-
Milano, Lombardia, Italy, 20133
- Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
-
Milano, Lombardia, Italy, 20141
- Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
-
-
Toscana
-
Pisa, Toscana, Italy, 56124
- A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii
-
-
Veneto
-
Padova, Veneto, Italy, 35128
- IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Fukuoka, Japan, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
Hiroshima, Japan, 730-8518
- Hiroshima City Hiroshima Citizens Hospital
-
Hiroshima, Japan, 734-8551
- Hiroshima University Hospital
-
Hyogo, Japan, 663-8501
- Hyogo Medical University Hospital
-
Hyogo, Japan, 650-0017
- Kobe University Hospital
-
Kyoto, Japan, 606-8507
- Kyoto University Hospital
-
Miyagi, Japan, 981-0914
- Sendai Kousei Hospital
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
Okayama, Japan, 710-8602
- Kurashiki Central Hospital
-
Osaka, Japan, 541-8567
- Osaka International Cancer Institute
-
Osaka, Japan, 534-0021
- Osaka City General Hospital
-
Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital
-
Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
Tokyo, Japan, 113-8431
- Juntendo University Hospital
-
Tokyo, Japan, 113-8677
- Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
-
-
-
-
-
Busan, Korea, Republic of, 49267
- Kosin University Gospel Hospital
-
Gyeonggi-do, Korea, Republic of, 16247
- St. Vincent's Hospital
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 08308
- Korea University Guro Hospital
-
Seoul, Korea, Republic of, 06273
- Gangnam Severance Hospital
-
-
-
-
-
Gdansk, Poland, 80-214
- Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
-
Kraków, Poland, 31-202
- Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II; Oddz. Klin. Chir. Klatki Piersiowej i Onkol.
-
Warszawa, Poland, 02-781
- Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers
-
-
-
-
Moskovskaja Oblast
-
Moscow, Moskovskaja Oblast, Russian Federation, 105229
- Main Military Clinical Hospital named after N.N. Burdenko
-
Moscow, Moskovskaja Oblast, Russian Federation, 115478
- FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
-
-
Sankt Petersburg
-
Saint-Petersburg, Sankt Petersburg, Russian Federation, 197758
- S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
-
St. Petersburg, Sankt Petersburg, Russian Federation, 197758
- Scientific Research Oncology Institute named after N.N. Petrov; Oncology
-
-
-
-
-
Belgrade, Serbia, 11080
- University Hospital Medical Center Bezanijska kosa
-
-
-
-
-
Golnik, Slovenia, 4204
- University Clinic Golnik
-
-
-
-
-
Johannesburg, South Africa, 2196
- Medical Oncology Centre of Rosebank; Oncology
-
Pretoria, South Africa
- Eugene Marais Hospital; Oncology
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron; Oncology
-
Madrid, Spain, 28027
- Clinica Universidad de Navarra Madrid; Servicio de Oncología
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos; Servicio de Oncologia
-
Malaga, Spain, 29011
- Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
-
Sevilla, Spain, 41009
- Hospital Universitario Virgen Macarena; Servicio de Oncologia
-
Valencia, Spain, 46010
- Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
-
Valencia, Spain, 46026
- Hospital Universitario la Fe; Servicio de Oncologia
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 8208
- Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
-
-
Islas Baleares
-
Palma de Mallorca, Islas Baleares, Spain, 07198
- Hospital Son Llatzer; Servicio de Oncologia
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universitaria de Navarra; Servicio de Oncologia
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
- Hospital de Basurto; Servicio de Oncologia
-
-
-
-
-
Linköping, Sweden, 58185
- Lungmedicinska kliniken, Centrum för kirurgi, ortopedi och cancervård, Universitetssjukhuset
-
Lund, Sweden, 22185
- Uni Hospital in Lund; Respiratory Medicine & Allergology
-
Stockholm, Sweden, 171 76
- Karolinska Universitetssjukhuset, Solna; Kliniska prövningsenheten Z:4:01
-
Uppsala, Sweden, 751 85
- Uppsala University Hospital; Department of Oncology
-
-
-
-
-
Lausanne, Switzerland, 1011
- CHUV; Departement d'Oncologie
-
Zürich, Switzerland, 8091
- UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology
-
Xitun Dist., Taiwan, 40705
- Taichung Veterans General Hospital
-
-
-
-
-
Bangkok, Thailand, 10330
- Chulalongkorn Hospital; Medical Oncology
-
ChiangMai, Thailand, 50200
- Maharaj Nakorn Chiang Mai Hospital; Department of Medicine
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49102
- Chemotherapy SI Dnipropetrovsk MA of MOHU
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Queen Elizabeth Hospital
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hosp NHS Trust;St James's Institute of Onc
-
Liverpool, United Kingdom, L7 8YA
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
London, United Kingdom, EC1A 7BE
- Barts and the London NHS Trust.
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85711
- Arizona Oncology
-
-
California
-
Los Angeles, California, United States, 90033
- USC Norris Cancer Center
-
Newport Beach, California, United States, 92663
- USC Norris Cancer Center; USC Oncology Hematology Newport Beach
-
Orange, California, United States, 92868
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
-
Sacramento, California, United States, 95817
- UC Davis Cancer Center; Oncology
-
San Diego, California, United States, 92037
- Scripps Clinic
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Center
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
Washington, District of Columbia, United States, 20010
- Washington Cancer Institute; Washington Hospital Center
-
-
Illinois
-
Peoria, Illinois, United States, 61615
- Illinois Cancer Care
-
-
Maine
-
Detroit, Maine, United States, 48201-2013
- Barbara Ann Karmanos Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Uni of Maryland Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0934
- University of Michigan
-
Brighton, Michigan, United States, 48116
- Brighton Center for Specialty Care
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Minnesota Oncology Minneapolis
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Rochester
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- Mercy Clinic Cancer & Hematology
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Nebraska Methodist Estabrook Cancer Center
-
-
New York
-
Lake Success, New York, United States, 11042
- Northwell Health; Monter Cancer Center
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10016
- NYU Langone Medical Center; Laura and Isaac Perlmutter Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Valley Health Network
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute / Tennessee Oncology
-
-
Texas
-
Austin, Texas, United States, 78745
- Texas Oncology - South Austin
-
Tyler, Texas, United States, 75701
- UT Health East Texas HOPE Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists, PC
-
-
Washington
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists - Vancouver
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
- Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
- Adequate pulmonary and cardiac function to undergo surgical resection
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end organ function
- Negative HIV test at screening
- Negative for active HBV and HCV at screening
- Adequate tissue for PD-L1 IHC assessment
Exclusion criteria:
- NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
- Mixed NSCLC and small cell lung cancer histology
- Any prior therapy for lung cancer
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
- Non-squamous NSCLC histology with activating ALK and EGFR mutation
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or evidence of active of active pneumonitis on screening chest Computed Tomography (CT) scan
- Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
- Severe infection within 4 weeks prior to randomization
- Significant history of cardiovascular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Atezolizumab + platinum-based chemotherapy
Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy Platinum-based chemotherapy may include:
Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab |
Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase
Other Names:
Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Cisplatin 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Gemcitabine 1250 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
|
Placebo Comparator: Arm B: Placebo + platinum-based chemotherapy
Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy Platinum-based chemotherapy may include:
Participants will receive best supportive care and monitoring after surgery |
Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Cisplatin 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Gemcitabine 1250 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Other Names:
Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)
Time Frame: Up to approximately 96 months
|
IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first.
|
Up to approximately 96 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response (pCR)
Time Frame: At time of surgery
|
pCR is defined as the absence of any viable primary tumor cells at the time of surgical resection in the primary tumor and all sampled lymph nodes as assessed by central and local pathology laboratory.
|
At time of surgery
|
Major Pathological Response (MPR)
Time Frame: At time of surgery
|
MPR is defined as ≤ 10% residual viable tumor cells at the time of surgical resection in the primary tumor, as assessed by central and local pathology laboratory.
|
At time of surgery
|
Objective Response (OR)
Time Frame: Prior to surgery, up to approximately 84 days
|
Objective response is defined as a complete response or partial response, as determined by the investigator according to RECIST v1.1
|
Prior to surgery, up to approximately 84 days
|
Overall Survival (OS)
Time Frame: Up to approximately 96 months
|
OS is defined as the time from randomization to death from any cause during the course of the study.
|
Up to approximately 96 months
|
Investigator-Assessed EFS
Time Frame: Up to approximately 96 months
|
EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the investigator; or death from any cause, whichever occurs first.
|
Up to approximately 96 months
|
Disease-Free Survival (DFS)
Time Frame: Up to approximately 96 months
|
DFS is defined as the time from the first date of no disease to local or distant recurrence (including occurrence of new primary NSCLC) or death due to any cause, whichever occurs first, as determined by the investigator during the adjuvant treatment and observation follow-up
|
Up to approximately 96 months
|
2-Year and 3-Year OS
Time Frame: Up to approximately 96 months
|
The 2-year and 3-year OS rate is defined as the probability that a participant will be alive 2 years and 3 years after randomization, respectively.
|
Up to approximately 96 months
|
2-Year and 3-Year Independent Review Facility-Assessed EFS
Time Frame: Up to approximately 96 months
|
EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Independent Review Facility.
|
Up to approximately 96 months
|
2-Year and 3-Year Investigator-Assessed EFS
Time Frame: Up to approximately 96 months
|
EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Investigator.
|
Up to approximately 96 months
|
Change from baseline in HRQoL scores
Time Frame: Up to approximately 96 months
|
Change from baseline in HRQoL scores as assessed through use of the two-item GHS/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30 at each assessment time point during the study through the completion of adjuvant treatment and observation follow-up assessments
|
Up to approximately 96 months
|
Percentage of Participants With Adverse Events (AEs)
Time Frame: Up to approximately 96 months
|
Up to approximately 96 months
|
|
Number and Severity of Surgical Related Adverse Events
Time Frame: Up to approximately 96 months
|
Up to approximately 96 months
|
|
Number of Surgical Delays
Time Frame: Up to approximately 96 months
|
Number of surgical delays.
|
Up to approximately 96 months
|
Length of Surgical Delays
Time Frame: Up to approximately 96 months
|
Length of surgical delays.
|
Up to approximately 96 months
|
Number of Operative and Post-Operative Complications
Time Frame: Up to approximately 96 months
|
Number of operative and post-operative complications.
|
Up to approximately 96 months
|
Reasons for Surgical Cancellations
Time Frame: Up to approximately 96 months
|
Reasons for surgical cancellations.
|
Up to approximately 96 months
|
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Time Frame: Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Cmin is the minimum (or trough) concentration that a study drug achieves in the body.
|
Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Time Frame: Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Cmax is the maximum (or peak) concentration that a study drug achieves in the body.
|
Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab
Time Frame: Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Folic Acid Antagonists
- Carboplatin
- Paclitaxel
- Antibodies
- Pemetrexed
- Atezolizumab
- Gemcitabine
Other Study ID Numbers
- GO40241
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small-Cell Lung
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
Clinical Trials on Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
-
Hoffmann-La RocheCompletedTumorsFrance, United States, Denmark, Ireland, Italy, Turkey, United Kingdom, Canada, Brazil, Spain, Poland, Netherlands, Germany, Russian Federation, Austria, Finland, Norway, Switzerland
-
Genentech, Inc.CompletedNon-Small Cell Lung CancerUnited States
-
Genentech, Inc.CompletedNeoplasmsUnited States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell LungChina, Korea, Republic of, Singapore, Thailand, Malaysia
-
Genentech, Inc.CompletedNon-Small Cell Lung CancerUnited States, France, United Kingdom, Belgium, Netherlands
-
Genentech, Inc.Completed
-
Hoffmann-La RocheCompletedColorectal CancerCanada, United States, Italy, Korea, Republic of, United Kingdom, Belgium, Russian Federation, Hong Kong, Spain, Australia, Poland
-
Hoffmann-La RocheCompletedSmall Cell Lung CarcinomaKorea, Republic of, United States, Hungary, Poland, China, France, Greece, Spain, United Kingdom, Brazil, Italy, Germany, Mexico, Australia, Serbia, Russian Federation, Japan, Austria, Chile, Czechia, Taiwan
-
Hoffmann-La RocheCompletedNon-Small Cell Lung CancerCanada, Belgium, Brazil, China, Denmark, Portugal, Spain, United Kingdom, Argentina, Bulgaria, Colombia, Germany, India, Ireland, Italy, Luxembourg, Mexico, Poland, Romania, Slovakia, Switzerland, Vietnam, Kazakhstan, Czechia
-
Hoffmann-La RocheCompletedRenal Cell CarcinomaKorea, Republic of, United States, France, Italy, United Kingdom, Canada, Australia, Brazil, Denmark, Spain, Turkey, Japan, Czechia, Singapore, Thailand, Taiwan, Russian Federation, Germany, Bosnia and Herzegovina, Poland, Mexico